We Analyzed the Future Direction of Turning Point Therapeutics Inc. (TPTX), Here is What We Found – News Heater
Home  »  Hot Stocks   »  We Analyzed the Future Direction of Turning Point ...

We Analyzed the Future Direction of Turning Point Therapeutics Inc. (TPTX), Here is What We Found

Turning Point Therapeutics Inc. (NASDAQ:TPTX) went up by 15.02% from its latest closing price compared to the recent 1-year high of $83.06. The company’s stock price has collected -5.60% of loss in the last five trading sessions.

Is It Worth Investing in Turning Point Therapeutics Inc. (NASDAQ :TPTX) Right Now?

The average price from analysts is $108.60, which is $80.23 above the current price. TPTX currently public float of 47.77M and currently shorts hold a 7.47% ratio of that float. Today, the average trading volume of TPTX was 650.30K shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


TPTX’s Market Performance

TPTX stocks went down by -5.60% for the week, with a monthly jump of 18.31% and a quarterly performance of -17.96%, while its annual performance rate touched -57.04%. The volatility ratio for the week stands at 14.03% while the volatility levels for the past 30 days are set at 12.10% for Turning Point Therapeutics Inc.. The simple moving average for the period of the last 20 days is -3.31% for TPTX stocks with a simple moving average of -35.30% for the last 200 days.

Analysts’ Opinion of TPTX

Stifel gave a rating of “Hold” to TPTX, setting the target price at $75 in the report published on September 30th of the previous year.

TPTX Trading at 2.33% from the 50-Day Moving Average

After a stumble in the market that brought TPTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.69% of loss for the given period.

Volatility was left at 12.10%, however, over the last 30 days, the volatility rate increased by 14.03%, as shares sank -5.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.62% lower at present.

During the last 5 trading sessions, TPTX fell by -5.60%, which changed the moving average for the period of 200-days by -55.19% in comparison to the 20-day moving average, which settled at $30.25. In addition, Turning Point Therapeutics Inc. saw -38.51% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at TPTX starting from Reich Siegfried, who sale 397 shares at the price of $36.30 back on Feb 09. After this action, Reich Siegfried now owns 3,448 shares of Turning Point Therapeutics Inc., valued at $14,411 using the latest closing price.

North Annette, the EVP & General Counsel of Turning Point Therapeutics Inc., sale 669 shares at $36.30 during a trade that took place back on Feb 09, which means that North Annette is holding 11,696 shares at $24,285 based on the most recent closing price.

Stock Fundamentals for TPTX

Current profitability levels for the company are sitting at:

  • -772.00 for the present operating margin
  • +87.13 for the gross margin

The net margin for Turning Point Therapeutics Inc. stands at -767.30. Equity return is now at value -22.90, with -22.00 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 21.08.

Leave a Comment

Your email address will not be published.




Download Free eBook For


100% free. stop anytime no spam